| __timestamp | ADMA Biologics, Inc. | Lantheus Holdings, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3742367 | 176081000 |
| Thursday, January 1, 2015 | 4311461 | 157939000 |
| Friday, January 1, 2016 | 6360761 | 164073000 |
| Sunday, January 1, 2017 | 29164321 | 169243000 |
| Monday, January 1, 2018 | 42194635 | 168489000 |
| Tuesday, January 1, 2019 | 39504238 | 172526000 |
| Wednesday, January 1, 2020 | 61291426 | 200649000 |
| Friday, January 1, 2021 | 79769341 | 237513000 |
| Saturday, January 1, 2022 | 118814535 | 353358000 |
| Sunday, January 1, 2023 | 169273000 | 586886000 |
Cracking the code
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis focuses on the cost of revenue trends for Lantheus Holdings, Inc. and ADMA Biologics, Inc. over the past decade. From 2014 to 2023, Lantheus Holdings, Inc. has seen a steady increase in its cost of revenue, peaking at approximately 587% of its 2014 value by 2023. This growth reflects the company's expanding operations and market reach. Meanwhile, ADMA Biologics, Inc. has experienced a dramatic rise, with its cost of revenue increasing by over 4,400% during the same period. This surge highlights ADMA's aggressive growth strategy and increased production capabilities. These insights provide a window into the financial health and strategic directions of these biotech firms, offering valuable information for potential investors and industry analysts.
Novo Nordisk A/S vs Lantheus Holdings, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for GSK plc and ADMA Biologics, Inc.
Viatris Inc. vs ADMA Biologics, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and ADMA Biologics, Inc.'s Expenses
Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Pharming Group N.V. vs Lantheus Holdings, Inc.
Cost of Revenue Comparison: Lantheus Holdings, Inc. vs MorphoSys AG
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Mesoblast Limited's Expenses
Analyzing Cost of Revenue: Lantheus Holdings, Inc. and Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Lantheus Holdings, Inc. vs Taro Pharmaceutical Industries Ltd.
Lantheus Holdings, Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: ADMA Biologics, Inc. vs MiMedx Group, Inc.